









Markets
/
Stocks
/
nasdaq-pstv
/

Plus Therapeutics Inc

PSTV

0.544USD

-0.001-0.15%

Market hours （ET）Quotes delayed by 15 min

71.61MMarket Cap

LossP/E TTM



Plus Therapeutics Inc

0.544

-0.001-0.15%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Plus Therapeutics Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Plus Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

123 / 407

Overall Ranking

255 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

7.750

Target Price

+1421.70%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Plus Therapeutics Inc Highlights

StrengthsRisks

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 2500.00% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 5.82M.

Undervalued

The company’s latest PE is -0.69, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.29M shares, decreasing 31.63% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 32.54K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.28.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 7.65, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 1.40M, representing a year-over-year decrease of 4.05%, while its net profit experienced a year-over-year decrease of 53.90%.

Score

Industry at a Glance

Previous score

7.65

Change



Financials

5.44

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

5.51

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.36

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

8.93

Key Metrics

Free cash flow

No Data

Plus Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 8.04, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.69, which is -88.89% below the recent high of -0.08 and -28.39% above the recent low of -0.89.

Score

Industry at a Glance

Previous score

8.04

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 123/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 8.00, which is equal to the Biotechnology & Medical Research industry's average of 8.00. The average price target for Plus Therapeutics Inc is 4.00, with a high of 21.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

7.750

Target Price

+1421.70%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Plus Therapeutics Inc

PSTV

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 5.55, which is lower than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 0.73 and the support level at 0.42, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.50

Change

0.05

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.030

Sell

RSI(14)

44.975

Neutral

STOCH(KDJ)(9,3,3)

28.256

Buy

ATR(14)

0.054

High Vlolatility

CCI(14)

-77.778

Neutral

Williams %R

72.256

Sell

TRIX(12,20)

-0.594

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

0.529

Buy

MA10

0.562

Sell

MA20

0.606

Sell

MA50

0.566

Sell

MA100

0.508

Buy

MA200

0.666

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 5.50%, representing a quarter-over-quarter increase of 44.62%. The largest institutional shareholder is The Vanguard, holding a total of 32.54K shares, representing 0.02% of shares outstanding, with 95.71% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

S.H.N. Financial Investments Ltd

1.50M

+69.40%

Hedrick (Marc H)

20.43K

Lenk (Robert P)

139.33K

+375.08%

Jane Street Capital, L.L.C.

117.45K

UBS Financial Services, Inc.

87.64K

+162.10%

Geode Capital Management, L.L.C.

51.18K

-10.30%

Sims Andrew (John Hugh MacIntyre)

9.81K

The Vanguard Group, Inc.

Star Investors

32.54K

Goldman Sachs & Company, Inc.

26.75K

Clowes (Howard)

26.50K

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 1.45, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.84. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.